Neha Krishnamohan
CIK 1866171 · Chief Financial Officer · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.84M
Companies
3
Total Filings
22
Lifetime Open-Market Net
-$939.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARQT | Director | 27,901 | $25.92 | $723.2K | -$939.5K | 6 | 2026-06-09 |
| ARTV | Chief Financial Officer | 99,356 | $11.22 | $1.11M | $0 | 4 | 2025-11-17 |
| Kinnate Biopharma Inc. (KNTE) Delisted | CHIEF FINANCIAL OFFICER | 64,087 | $2.65 | $169.8K | $0 | 10 | 2024-03-05 |
Recent Filings · Page 2 of 3
22 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-05 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −1,506 | -$3.9K | EDGAR |
| 2023-12-05 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −1,459 | -$3.3K | EDGAR |
| 2023-09-06 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −1,459 | -$3.4K | EDGAR |
| 2023-06-05 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −1,459 | -$6.3K | EDGAR |
| 2023-06-02 | ARQT | Grant (A) | +4,375 | $0 | EDGAR |
| 2023-03-03 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −1,721 | -$9.0K | EDGAR |
| 2023-02-14 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-02 | Kinnate Biopharma Inc. (KNTE) Delisted | Tax (F) | −1,459 | -$11.3K | EDGAR |
| 2022-09-06 | ARQT | Grant (A) | — | $0 | EDGAR |
| 2022-09-02 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | +67,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.